Abstract
No public abstract is available from the verified source records.
Xiaojie Xie
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease
10.1056/nejmoa1612790 · 2017
Evinacumab for homozygous familial hypercholesterolemia
10.1056/nejmoa2004215 · 2020
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia
10.1056/nejmoa2404147 · 2024
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
10.1016/s2213-8587(25)00290-6 · 2026
Angiopoietin-like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: a phase 2 study
10.1016/j.jacc.2025.03.008 · 2025
Efficacy and safety of quarterly dosing SHR-1918 in patients with suboptimally controlled hyperlipidemia
2026
Anti-ANGPTL3 antibody SHR-1918 for homozygous familial hypercholesterolemia: a nonrandomized clinical trial
10.1001/jamacardio.2025.4878 · 2026
Evolocumab and clinical outcomes in patients with cardiovascular disease
10.1056/nejmoa1615664 · 2017
Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease
10.1001/jama.2018.20045 · 2019
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial
10.1093/eurjpc/zwae090 · 2024
No additional external references are available.